Literature DB >> 16036077

Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study.

John C Stevenson1.   

Abstract

Hormone replacement therapy (HRT) is a collective term to include a variety of sex steroids, estrogens, and progestogens, given to postmenopausal women at various doses and administered through various routes. HRT is used for the relief of menopausal symptoms, with many women experiencing considerable improvement in their quality of life. It is also used for the prevention and treatment of osteoporosis, which is as effective as other available therapies. Other potential benefits of HRT are the prevention of cardiovascular disease and dementia. The main risks of HRT are an increased incidence of breast cancer and a transient increase in venous thromboembolism. The Women's Health Initiative is the largest randomized clinical trial of HRT to date, and has demonstrated benefits and risks of one specific HRT regimen. Skeletal benefits have been confirmed in terms of fracture reduction, as has a small risk of breast cancer development. Further studies of other HRT regimens are urgently required to clarify the cardiovascular effects.

Entities:  

Mesh:

Year:  2004        PMID: 16036077     DOI: 10.1007/s11914-004-0009-z

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  19 in total

1.  Coronary heart disease in women.

Authors:  J C Stevenson; M Flather; P Collins
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

Review 2.  Cardiovascular effects of oestrogens.

Authors:  J C Stevenson
Journal:  J Steroid Biochem Mol Biol       Date:  2000-11-30       Impact factor: 4.292

3.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

Authors: 
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

4.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.

Authors:  F Grodstein; P A Newcomb; M J Stampfer
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

5.  Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

Authors:  Pierre D Delmas; Kristine E Ensrud; Jonathan D Adachi; Kristine D Harper; Somnath Sarkar; Carlo Gennari; Jean-Yves Reginster; Huibert A P Pols; Robert R Recker; Steven T Harris; Wentao Wu; Harry K Genant; Dennis M Black; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

6.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

7.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

8.  Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.

Authors:  J C Gallagher; D J Baylink; R Freeman; M McClung
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

Review 9.  Coronary artery disease in women. Risk factors, evaluation, treatment, and prevention.

Authors:  F E Kuhn; C E Rackley
Journal:  Arch Intern Med       Date:  1993-12-13

10.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

View more
  4 in total

1.  Blood and interstitial flow in the hierarchical pore space architecture of bone tissue.

Authors:  Stephen C Cowin; Luis Cardoso
Journal:  J Biomech       Date:  2014-12-31       Impact factor: 2.712

2.  Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone.

Authors:  Yong-qi Li; Xiang-hui Xing; Hui Wang; Xi-li Weng; Shi-bin Yu; Guang-ying Dong
Journal:  Acta Pharmacol Sin       Date:  2011-11-28       Impact factor: 6.150

3.  Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status.

Authors:  Jisen Dai; Jinlong Jian; Maarten Bosland; Krystyna Frenkel; Güenther Bernhardt; Xi Huang
Journal:  Breast       Date:  2007-10-24       Impact factor: 4.380

Review 4.  Cardiovascular disease and osteoporosis: balancing risk management.

Authors:  Darren E R Warburton; Crystal Whitney Nicol; Stephanie N Gatto; Shannon S D Bredin
Journal:  Vasc Health Risk Manag       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.